logo
Share SHARE
FONT-SIZE Plus   Neg

Novartis To Add Warning On Blood Pressure Drug Rasilez On CHMP Recommendation

Novartis AG (NVS) Friday reported the conclusion of a risk-benefit review of its high blood pressure drug Rasilez by the European Medicines Agency's, or EMA's, Committee for Medicinal Products for Human Use, or CHMP. The Committee recommended that the product information for Rasilez in the EU should warn against use by patients who are also taking an ACE inhibitor or an ARB.

The review, which followed Novartis's decision to terminate its ALTITUDE study in the wake of a high incidence of adverse events, found that patients who have diabetes or mild-to-moderate renal impairment should consult a physician before using a combination product containing aliskiren, for which Rasilez is the trade name. The update also applies to other aliskiren products such as Sprimeo, Riprazo and Rasilamlo.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Maternity leave is a temporary period of absence from employment granted to expectant or new mothers during the months immediately before and after their pregnancy. Parental leave, including maternity, paternity and adoption leave, is an employee benefit. Many countries around the world, including... Texas, the second largest state in the U.S., has four of the five fastest-growing cities in the U.S., according to new population estimates released Thursday by the U.S. Census Bureau for the twelve months up to July 1, 2016. Ten of the fifteen fastest growing large U.S. cities during that 12-month span were in the South, according to the Census Bureau. To book-lover's surprise, online retailer Amazon opened another bricks and mortar store in an upmarket shopping mall in New York. This is the seventh book store of Amazon.
comments powered by Disqus
Follow RTT